Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > NEWS IS ON THE HORIZON

<< Previous

Bullboard Posts

Next >>

Comment by bligickaon Jan 26, 2021 10:12am

60 Views

Post# 32386435

RE: NEWS IS ON THE HORIZON

All I'm seeing is red.....

Charleyfarley wrote:
January 26th is a day to be savoured as the Vaxil of old reaches a Corporate Milestone. Insiders have made their intentions known and have set the bar high . The stakes are now in the process of being raised beyond all expectations .

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale